A gradual acceptance among physicians has been observed in adopting quality care initiatives that provide cost-saving, improved patient experience in cancer care, noted Kerin Adelson, MD, of Smilow Cancer Hospital at Yale New Haven/Yale Cancer Center.
Over time, a gradual acceptance among physicians has been observed in adopting quality care initiatives that provide cost-saving, improved patient experience in cancer care, said Kerin Adelson, MD, associate professor, chief quality officer, and deputy chief medical officer for Smilow Cancer Hospital at Yale New Haven/Yale Cancer Center.
Transcript
AJMC®: How has the reception to quality care initiatives among physicians evolved over time?
Dr Adelson: So, I think that there has been a gradual acceptance that data is honest and that we all have to sort of look at the data and incorporate that into evaluation of our practice. I think for many, many years, the doctor knew best, and to some extent may still, but there was initial resistance to imposing practice standards on somebody's individual practice, that they were the advocate for their patient and outside standards may not sort of reflect the doctor-patient relationship or may even get in the way of it.
I think that there is gradual understanding that evidence-based medicine matters, that the data about how we practice is actually relevant to the care that we give and to the cost of care, and that overutilization is both costly and can actually harm the patient experience by increasing the burden of care or the treatment burden on a patient.
So, I think that sort of the sweet spot is the idea that patients don't want to spend all their time in a CAT scanner if they don't need to, and they don't want to spend all their time getting procedures that could be avoided. So, it is understanding that sometimes appropriate utilization will both save money and improve patient experience–where the alignment occurs–and that is sort of the selling point, I think, for quality initiatives.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Frameworks for Advancing Health Equity: Trans and Gender Diverse Health Care
June 28th 2024Charlie Borowicz, manager of trans and gender diverse health at Allegheny Health Network, shares how the program offers comprehensive patient-first care to those in the LGBTQ+ and gender diverse community.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More